Meeting
2017 ASCO Annual Meeting
Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer.
Authors
Maryann J. Kwa
New York University Cancer Institute, New York, NY
Maryann J. Kwa , Alyssa Iwano , Francisco J. Esteva , Yelena Novik , James L. Speyer , Ruth Oratz , Marleen Iva Meyers , Deborah M. Axelrod , Rebecca Hogan , Sandra Mendoza , Judith D. Goldberg , Franco Muggia , Sylvia Adams
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT02752685
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS1124)
DOI
10.1200/JCO.2017.35.15_suppl.TPS1124
Abstract #
TPS1124
Poster Bd #
107a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Preliminary results from a single-arm, phase II study assessing the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer.
First Author: Alice Ho
Poster
2019 ASCO Annual Meeting
Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
First Author: Adam Brufsky
Poster
2018 ASCO Annual Meeting
Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).
First Author: Zachary William Neil Veitch